Literature DB >> 31917152

Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.

Adam L Halberstadt1, Muhammad Chatha2, Adam K Klein2, Jason Wallach3, Simon D Brandt4.   

Abstract

Serotonergic hallucinogens such as lysergic acid diethylamide (LSD) induce head twitches in rodents via 5-HT2A receptor activation. The goal of the present investigation was to determine whether a correlation exists between the potency of hallucinogens in the mouse head-twitch response (HTR) paradigm and their reported potencies in other species, specifically rats and humans. Dose-response experiments were conducted with phenylalkylamine and tryptamine hallucinogens in C57BL/6J mice, enlarging the available pool of HTR potency data to 41 total compounds. For agents where human data are available (n = 36), a strong positive correlation (r = 0.9448) was found between HTR potencies in mice and reported hallucinogenic potencies in humans. HTR potencies were also found to be correlated with published drug discrimination ED50 values for substitution in rats trained with either LSD (r = 0.9484, n = 16) or 2,5-dimethoxy-4-methylamphetamine (r = 0.9564, n = 21). All three of these behavioral effects (HTR in mice, hallucinogen discriminative stimulus effects in rats, and psychedelic effects in humans) have been linked to 5-HT2A receptor activation. We present evidence that hallucinogens induce these three effects with remarkably consistent potencies. In addition to having high construct validity, the HTR assay also appears to show significant predictive validity, confirming its translational relevance for predicting subjective potency of hallucinogens in humans. These findings support the use of the HTR paradigm as a preclinical model of hallucinogen psychopharmacology and in structure-activity relationship studies of hallucinogens. Future investigations with a larger number of test agents will evaluate whether the HTR assay can be used to predict the hallucinogenic potency of 5-HT2A agonists in humans. "This article is part of the special issue entitled 'Serotonin Research: Crossing Scales and Boundaries'. Published by Elsevier Ltd.

Entities:  

Keywords:  Behavioral model; DMT; DOM; Head shake; Mescaline; N,N-dimethyltryptamine; NBOMe; Psilocybin; Psychedelic

Mesh:

Substances:

Year:  2020        PMID: 31917152      PMCID: PMC9191653          DOI: 10.1016/j.neuropharm.2019.107933

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.273


  133 in total

1.  Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling.

Authors:  Kelly A Jones; Deepak P Srivastava; John A Allen; Ryan T Strachan; Bryan L Roth; Peter Penzes
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-04       Impact factor: 11.205

Review 2.  Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan.

Authors:  Erick H Turner; Jennifer M Loftis; Aaron D Blackwell
Journal:  Pharmacol Ther       Date:  2005-07-14       Impact factor: 12.310

3.  Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.

Authors:  A P Monte; D Marona-Lewicka; A Kanthasamy; E Sanders-Bush; D E Nichols
Journal:  J Med Chem       Date:  1995-03-17       Impact factor: 7.446

4.  Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.

Authors:  Didier Cussac; Elisa Boutet-Robinet; Marie-Christine Ailhaud; Adrian Newman-Tancredi; Jean-Claude Martel; Nathalie Danty; Isabelle Rauly-Lestienne
Journal:  Eur J Pharmacol       Date:  2008-07-30       Impact factor: 4.432

5.  Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.

Authors:  R A Glennon; M Titeler; J D McKenney
Journal:  Life Sci       Date:  1984-12-17       Impact factor: 5.037

6.  Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives.

Authors:  A J Hoffman; D E Nichols
Journal:  J Med Chem       Date:  1985-09       Impact factor: 7.446

Review 7.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

8.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

9.  Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Int J Neuropsychopharmacol       Date:  2018-10-01       Impact factor: 5.176

10.  Psychedelics Promote Structural and Functional Neural Plasticity.

Authors:  Calvin Ly; Alexandra C Greb; Lindsay P Cameron; Jonathan M Wong; Eden V Barragan; Paige C Wilson; Kyle F Burbach; Sina Soltanzadeh Zarandi; Alexander Sood; Michael R Paddy; Whitney C Duim; Megan Y Dennis; A Kimberley McAllister; Kassandra M Ori-McKenney; John A Gray; David E Olson
Journal:  Cell Rep       Date:  2018-06-12       Impact factor: 9.423

View more
  37 in total

1.  Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice.

Authors:  Mario de la Fuente Revenga; Urjita H Shah; Nima Nassehi; Alaina M Jaster; Prithvi Hemanth; Salvador Sierra; Malgorzata Dukat; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2021-01-05       Impact factor: 4.418

Review 2.  Psychedelics.

Authors:  Benjamin Kelmendi; Alfred P Kaye; Christopher Pittenger; Alex C Kwan
Journal:  Curr Biol       Date:  2022-01-24       Impact factor: 10.834

3.  Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents.

Authors:  Alaina M Jaster; Harrison Elder; Samuel A Marsh; Mario de la Fuente Revenga; S Stevens Negus; Javier González-Maeso
Journal:  Psychopharmacology (Berl)       Date:  2022-03-02       Impact factor: 4.530

Review 4.  The promises and perils of psychedelic pharmacology for psychiatry.

Authors:  Tristan D McClure-Begley; Bryan L Roth
Journal:  Nat Rev Drug Discov       Date:  2022-03-17       Impact factor: 84.694

5.  Investigation of the Structure-Activity Relationships of Psilocybin Analogues.

Authors:  Adam K Klein; Muhammad Chatha; Lauren J Laskowski; Emilie I Anderson; Simon D Brandt; Stephen J Chapman; John D McCorvy; Adam L Halberstadt
Journal:  ACS Pharmacol Transl Sci       Date:  2020-12-14

6.  Discriminative Stimulus Effects of Substituted Tryptamines in Rats.

Authors:  Michael B Gatch; Adam Hoch; Theresa M Carbonaro
Journal:  ACS Pharmacol Transl Sci       Date:  2020-12-29

7.  Psychedelic-inspired drug discovery using an engineered biosensor.

Authors:  Chunyang Dong; Calvin Ly; Lee E Dunlap; Maxemiliano V Vargas; Junqing Sun; In-Wook Hwang; Arya Azinfar; Won Chan Oh; William C Wetsel; David E Olson; Lin Tian
Journal:  Cell       Date:  2021-04-28       Impact factor: 41.582

Review 8.  A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics.

Authors:  Neil K Savalia; Ling-Xiao Shao; Alex C Kwan
Journal:  Trends Neurosci       Date:  2020-12-21       Impact factor: 13.837

Review 9.  Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.

Authors:  David E Olson
Journal:  Biochemistry       Date:  2022-01-21       Impact factor: 3.162

10.  25CN-NBOMe Metabolites in Rat Urine, Human Liver Microsomes and C.elegans-Structure Determination and Synthesis of the Most Abundant Metabolites.

Authors:  Anna Šuláková; Jitka Nykodemová; Petr Palivec; Radek Jurok; Silvie Rimpelová; Tereza Leonhardt; Klára Šíchová; Tomáš Páleníček; Martin Kuchař
Journal:  Metabolites       Date:  2021-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.